Skip to content
AnalystLens

Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Dec 3, 2025)

Reports
Regulation FD
Filing Date
Filed December 3, 2025
Period End
December 3, 2025
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Jan ’22Jan ’22
  4. Leadership change8-K · Jan ’24Jan ’24

Summary

Summary of the 8-K filed December 3, 2025. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. ("Charles River") filed this Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) to announce that management will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025, at approximately 10:00 a.m.

Eastern time. The filing states that management intends to address certain fourth-quarter demand trends, specifically trends in Discovery and Safety Assessment (DSA) booking activity and related key performance indicators. The key disclosed update is that DSA net book-to-bill has continued to improve each month since the beginning of the third fiscal quarter of 2025.

The Company also notes that seasonality during the fourth-quarter holiday period and early January may affect near-term proposal and booking activity, and says it is encouraged by the positive momentum and upward trends since the middle of fiscal 2025. The filing does not provide specific net book-to-bill values, revenue, or earnings figures. The information is furnished rather than filed, so it is not incorporated into Securities Act or Exchange Act filings unless expressly referenced.

The filing includes forward-looking statement cautions covering DSA demand, proposal and booking trends, and refers readers to the risk factors in the Company's 2024 Form 10-K and its Form 10-Q for the quarter ended September 27, 2025. The Company disclaims any duty to update these statements except as required by law.

Key Highlights

  1. DSA net book-to-bill has continued to improve each month since the beginning of the third fiscal quarter of 2025.
  2. Management is presenting at the Evercore 8th Annual Healthcare Conference on December 3, 2025, at approximately 10:00 a.m. Eastern time.
  3. Management plans to address fourth-quarter demand trends, focusing on Discovery and Safety Assessment (DSA) bookings and related KPIs.
  4. Holiday seasonality in the fourth quarter and early January may affect near-term proposal and booking activity.
  5. Management says it is encouraged by positive momentum and upward trends in DSA since the middle of fiscal 2025.
  6. The information is furnished under Item 7.01 (Regulation FD) and is not deemed filed under the Exchange Act or Securities Act.
  7. The filing does not disclose specific book-to-bill ratios, revenue, or earnings figures.

Frequently Asked Questions

  1. What is the key operational update Charles River is providing?

    The Company states that DSA net book-to-bill has continued to improve each month since the beginning of the third fiscal quarter of 2025. The filing does not give the actual ratio values.

  2. When and where will management discuss these trends?

    Management will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025, at approximately 10:00 a.m. Eastern time.

  3. Does management expect seasonality to affect near-term bookings?

    Yes. The Company notes that seasonality during the fourth-quarter holiday period and in early January may impact near-term proposal and booking activity, though it is encouraged by the positive momentum since the middle of fiscal 2025.

  4. Is this information considered filed for legal purposes?

    No. The filing states that the information is furnished under Regulation FD and shall not be deemed filed under Section 18 of the Exchange Act or incorporated by reference into other filings unless expressly stated.

  5. What risks does the company identify for these forward-looking statements?

    The filing identifies risks related to demand, proposal and booking trends, including net book-to-bill, in the DSA segment. It refers investors to the risk factors in the 2024 Form 10-K and the Form 10-Q for the quarter ended September 27, 2025.